[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338543-105":59,"doc-detail-338543-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","quantifying-overdiagnosis-for-multicancer-detection-tests-a-novel-method","Quantifying Overdiagnosis for Multicancer Detection Tests - A Novel Method","","Multicancer detection (MCD) tests use blood specimens to detect preclinical cancers, raising a central safety concern: overdiagnosis, defined as detecting preclinical cancer at screening that would not become symptomatic without screening. Because overdiagnosis is not directly observed, estimating the screen overdiagnosis fraction (SOF) is difficult, especially for rapidly evolving MCD technologies. This work introduces a novel SOF estimation method for yearly testing programs using at least two yearly tests across a wide age range, supported by robustness to key modeling assumptions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/quantifying-overdiagnosis-for-multicancer-detection-tests-a-novel-method/338543/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/quantifying-overdiagnosis-for-multicancer-detection-tests-a-novel-method/338543.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the screen overdiagnosis fraction (SOF) measure in multicancer detection tests?","Question",{"text":112,"@type":113},"SOF is the probability of overdiagnosis at screen detection, capturing the chance that a screened-detected preclinical cancer would not have become symptomatic without screening.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is quantifying overdiagnosis difficult for screening tests?",{"text":117,"@type":113},"Overdiagnosis is not directly observed, so there is no straightforward way to measure it from screened outcomes alone. Estimating SOF is especially challenging for MCD tests because short-term results are needed as the technology rapidly changes.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the key requirements and assumptions of the proposed novel method?",{"text":121,"@type":113},"The method estimates average SOF for programs of yearly MCD tests that provide at least two yearly tests to persons across a wide range of ages. It applies to cancers with no conventional screening and assumes an exponential distribution for sojourn time in an operational screen-detectable preclinical cancer state.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338543,1790168410,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Statistics in Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nQuantifying Overdiagnosis for Multicancer Detection Tests: A Novel Method  \nStuart G. Baker   \nDivision of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA Correspondence: Stuart G. Baker ([sb16i@nih.gov](sb16i@nih.gov))  \nReceived: 3 June 2024 | Revised: 29 October 2024 | Accepted: 3 November 2024  \nFunding: This work was supported by Division of Cancer Prevention, National Cancer Institute.  \nKeywords: cancer screening | lead time | multicancer early detection test | overdiagnosis  \nABSTRACT  \nMulticancer detection (MCD) tests use blood specimens to detect preclinical cancers. A major concern is overdiagnosis, the detection of preclinical cancer on screening that would not have developed into symptomatic cancer in the absence of screening. Because overdiagnosis can lead to unnecessary and harmful treatments, its quantification is important. A key metric is the screen overdiagnosis fraction (SOF), the probability of overdiagnosis at screen detection. Estimating SOF is notoriously difficult because overdiagnosis is not observed. This estimation is more challenging with MCD tests because short-term results are needed as the technology is rapidly changing. To estimate average SOF for a program of yearly MCD tests, I introduce a novel method that requires at least two yearly MCD tests given to persons having a wide range of ages and applies only to cancers for which there is no conventional screening. The method assumes an exponential distribution for the sojourn time in an operational screen-detectable preclinical cancer (OPC) state, defined as once screen-detectable (positive screen and work-up), always screen-detectable. Because this assumption appears in only one term in the SOF formula, the results are robust to violations ofthe assumption. An SOF plot graphs average SOF versus mean sojourn time. With lung cancer screening data and synthetic data, SOF plots distinguished small from moderate levels ofSOF. With its unique set of assumptions, the SOF plot would complement other modeling approaches for estimating SOF once sufficient short-term observational data on MCD tests become available.  \n1 | Introduction  \nThe goal of cancer screening is to detect preclinical cancers, asymptomatic changes thought to indicate carcinogenesis, with the hope that early intervention will reduce cancer mortality. Multicancer detection (MCD) tests based on blood or urine specimens have the potential to detect preclinical cancer in many cancers for which there is no conventional screening technology. These technologies typically involve abnormal methylation, fragmentation patterns, mutations in cell-free DNA, and protein markers in exosomes [1] .  \nA major concern with cancer screening and particularly MCD tests is overdiagnosis, the screen–detection of a preclinical cancer that would not have developed into symptomatic cancer in the absence of screening [1, 2] . I define screen detection as a positive screening test followed by a work-up that indicates preclinical cancer. My focus is overdiagnosis for specific cancers in an MCD test.  \nBecause overdiagnosis can lead to unnecessary and harmful treatment, quantifying the amount of overdiagnosis is important. Two metrics for quantifying overdiagnosis are (i) the screen  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nPublished 2024 . This article is a U.S. Government work and is in the public domain in the USA. Statistics in Medicine published by John Wiley & Sons Ltd.  \nStatistics in Medicine, 2024; 43:5935–5943 5935  \n[https://doi.org/10.1002/sim.10285](https://doi.org/10.1002/sim.10285)  \noverdiagnosis fraction (SOF), the probability of overdiagnosis at screen detection, and (ii) the screen-interval overdiagnosis fraction (SIOF), the probability of overdiagnosis a","cbCaiuvtyY383KSx","https://ap.wps.com/l/cbCaiuvtyY383KSx","pdf",2204517,"English","# Introduction\n# Review of Methods to Quantify Overdiagnosis\n## Stop-Screen Trial\n## Population Trend Analysis","[{\"question\":\"What does the screen overdiagnosis fraction (SOF) measure in multicancer detection tests?\",\"answer\":\"SOF is the probability of overdiagnosis at screen detection, capturing the chance that a screened-detected preclinical cancer would not have become symptomatic without screening.\"},{\"question\":\"Why is quantifying overdiagnosis difficult for screening tests?\",\"answer\":\"Overdiagnosis is not directly observed, so there is no straightforward way to measure it from screened outcomes alone. Estimating SOF is especially challenging for MCD tests because short-term results are needed as the technology rapidly changes.\"},{\"question\":\"What are the key requirements and assumptions of the proposed novel method?\",\"answer\":\"The method estimates average SOF for programs of yearly MCD tests that provide at least two yearly tests to persons across a wide range of ages. It applies to cancers with no conventional screening and assumes an exponential distribution for sojourn time in an operational screen-detectable preclinical cancer state.\"}]","Quantifying Overdiagnosis for Multicancer Detection Tests - A Novel Method | PDF",1790024130,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94501c0c49d9c7c5097d3e74561a53a6.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/746fcfb82369ba4a59d74a80edf6def9.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/998142b00a51809c22dc7def61cb10d2.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5947088c679d1052c5fb0f23dd1fd823.webp",980,1287]